Skip to content

Group Sites
  • International
  • Asia Pacific
  • South Africa
  • Sub-Saharan Africa
OUR RESPONSE TO COVID-19
sub-saharan-header
Group Business Sub-Saharan Africa

SUB-SAHARAN AFRICA

Within the Sub-Saharan Africa business local brands have strong brand equity and continue to contribute positively to Aspen’s leading presence in the South African market. We also supply OTC brands in various home markets outside South Africa, mainly in Namibia, Botswana, Tanzania, Kenya, Nigeria, Ghana and Uganda.

Key Countries

Botswana
Kenya
Namibia
South Africa
Tanzania

sub-saharan-africa
  • The South African private pharmaceutical sector was valued at
    R45,4 billion for the MAT period July 2020.
  • In South Africa, four out of the top 10 brands in the private sector were Aspen (and Ethicare) products.
  • Aspen (and Ethicare) is ranked as the number one pharmaceutical company in the South African private sector with an 11,9% share by value.

* South Africa only, rest of sub-Saharan Africa (“SSA”) not covered by IQVIA.
Source: IQVIA – July 2020

STATISTICS

Number of products launched:

22

(2019: 22)

Average staff turnover†:

10%

(2019: 11%)

Number of product recalls:

5

(2019: 5)

Number of work-related fatalities:

Nil

(2019: Nil)

Number of permanent employees

4 034

June 2020

4 167

June 2019

*Rate excludes employees transferred in Nutritionals disposal.

Revenue 2020
R’million		 2019 (CER)
R’million		 Change
%
Regional Brands 7 070 6 691 6
Sterile Focus Brands 124 119 4
Anaesthetics Brands 118 112 5
Thrombosis Brands 6 7 (14)
Total Commercial Pharmaceuticals 7 194 6 810 6
Manufacturing 686 613 12
FDF 314 253 24
API 372 360 3
Total 7 880 7 423 6

Note: Commercial Pharmaceuticals revenue by customer geography and anufacturing revenue by place of manufacture.

Scroll To Top